NovoCure (NASDAQ: NVCR) director adds shares through 2025 employee stock purchase plan

Rhea-AI Filing Summary

NovoCure Ltd director Asaf Danziger acquired 268 ordinary shares through the company’s 2025 Employee Share Purchase Plan (ESPP). The shares were purchased for $11.15 per share for the ESPP purchase period from January 1, 2026 through June 30, 2026.

Under the ESPP, the purchase price was set at 85% of the closing price of NovoCure’s ordinary shares on January 1, 2026, making this a routine compensation-related acquisition rather than an open-market trade. Following this transaction, Danziger directly owns 416,742 ordinary shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Danziger Asaf

Role null

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	268	$11.15	$3K

Holdings After Transaction: Ordinary Shares — 416,742 shares (Direct, null)

Footnotes (1)

1. The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.

Key Figures

Shares acquired: 268 shares Purchase price: $11.15 per share Post-transaction holdings: 416,742 shares +2 more

5 metrics

Shares acquired 268 shares Ordinary shares acquired via 2025 ESPP purchase period Jan 1–Jun 30, 2026

Purchase price $11.15 per share Price for ESPP acquisition of 268 NovoCure ordinary shares

Post-transaction holdings 416,742 shares Total ordinary shares directly owned by Asaf Danziger after the transaction

ESPP discount basis 85% of closing price ESPP purchase price based on 85% of Jan 1, 2026 closing price

Rule 16b-3(c) exemption Applies ESPP acquisition described as exempt under Rule 16b-3(c)

Key Terms

Employee Share Purchase Plan, ESPP, Rule 16b-3(c), Ordinary Shares

4 terms

Employee Share Purchase Plan financial

"The reporting person is voluntarily reporting the acquisition of shares ... pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP")."

A program that lets employees buy their employer’s stock, often through regular payroll deductions and sometimes at a discounted price or with matching contributions; think of it as a company-run savings plan that converts part of pay into ownership. It matters to investors because it can increase insider ownership and employee motivation, potentially affecting company performance, and can slightly change share supply when new stock is issued or sold.

ESPP financial

"In accordance with the ESPP, these shares were purchased based on 85% of the closing price..."

An Employee Stock Purchase Plan (ESPP) is a company program that lets employees buy the company’s shares at a reduced price, usually by setting aside a small portion of their pay over time. It matters to investors because it encourages employees to own part of the business—like giving staff a discounted membership— which can boost commitment and performance, while also potentially increasing the number of shares available and affecting shareholder value.

Rule 16b-3(c) regulatory

"This transaction is also exempt under Rule 16b-3(c)."

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

Ordinary Shares financial

"The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan..."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 04:30 PM Accepted by SEC EDGAR 07/01/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Danziger Asaf

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/30/2026		A	V	268	A	$11.15(2)	416,742	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).

2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.

Remarks:

	Steven Robbins, as attorney in fact for Danziger, Asaf	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did NovoCure (NVCR) report for Asaf Danziger?

NovoCure reported that director Asaf Danziger acquired 268 ordinary shares under the company’s 2025 Employee Share Purchase Plan. This was a routine, compensation-related purchase rather than an open-market trade and increased his direct ownership to 416,742 shares.

At what price were the new NovoCure (NVCR) shares acquired in the ESPP?

The 268 NovoCure ordinary shares were acquired at $11.15 per share through the Employee Share Purchase Plan. The plan price was based on 85% of the closing price of NovoCure’s ordinary shares on January 1, 2026.

How many NovoCure (NVCR) shares does Asaf Danziger own after this Form 4 transaction?

After this transaction, director Asaf Danziger directly owns 416,742 NovoCure ordinary shares. The filing shows his position increased by 268 shares purchased through the 2025 Employee Share Purchase Plan for the period January 1, 2026 to June 30, 2026.

What is the NovoCure (NVCR) 2025 Employee Share Purchase Plan mentioned in the filing?

The 2025 Employee Share Purchase Plan allows eligible NovoCure participants to buy ordinary shares at a discount. In this case, shares were purchased at 85% of the closing price on January 1, 2026 for the January–June 2026 purchase period.

Is the NovoCure (NVCR) insider acquisition exempt under SEC rules?

Yes. The filing states this ESPP acquisition is exempt under SEC Rule 16b-3(c). That rule generally provides exemptions for certain employee benefit plan transactions, treating them as routine compensation rather than discretionary open-market trading activity by insiders.